Clinical RisksThe VITESSE trial in peanut-allergic children (4–7 years) represents the last major clinical risk for Viaskin, with the Phase 3 trial fully enrolled and using a modified patch informed by previous studies.
Commercialization RisksInvestors now have the goal line for Viaskin Peanut in sight, which is relatively derisked, and can start evaluating the commercial opportunity which could be ~$2B+ annually.
Financial ChallengesDBVT ended the year with $33M in cash which management said is sufficient to fund operations into April, so management will need to bring in capital immediately.